C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Company Overview - C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on targeted protein degradation science to develop new medicines that can transform patients' lives [3] - The company is advancing targeted oncology programs through clinical studies and utilizing its TORPEDO® platform to design and optimize small-molecule medicines for difficult-to-treat diseases [3] Leadership Changes - Ron Cooper has been appointed as the new chairman of C4T's Board of Directors, bringing extensive experience from his previous roles, including president and CEO of Albireo Pharma and nearly 30 years at Bristol-Myers Squibb [6][7] - Bruce Downey, who served as chairman from June 2022 to June 2024, will remain a member of the Board of Directors [6] - Glenn Dubin has stepped down from the Board, allowing for the integration of Ron Cooper's pharmaceutical and biotechnology expertise [2][6] Strategic Vision - The company aims to become a fully integrated biotechnology company, leveraging Ron Cooper's experience in successfully bringing products through discovery, development, and commercialization [2][6] - C4T is focused on advancing its pipeline to deliver on the potential of targeted protein degradation science for patients seeking new therapies [2]